Bekemv®
ACTIVE PRINCIPLE:
eculizumab
INDICATION:
paroxysmal hemoglobinuria
DATE:
27/04/2023
STATUS:
Authorized
Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE:
eculizumab
INDICATION:
paroxysmal hemoglobinuria
DATE:
27/04/2023
STATUS:
Authorized
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.